Antiviral Research

Antiviral Research

  • Volume 12
  • Issue 12
  • ISSN 0166-3542
  • SCImago Journal Rank (SJR): 2.052
  • Source Normalized Impact per Paper (SNIP): 1.956
  • Impact Factor: 5.97
  • Five Year Impact Factor: 5.801
Editor-in-chief: Bray

Subscription options

Sales tax will be calculated at check-out
Subscription length
Print - Annual Subscription
(Jan - Dec 2021)
Next planned ship date: Nov 22, 2021

Description

Antiviral Research publishes research reports, short communications, review articles and commentaries on the control of viral infections in humans and animals. Its scope encompasses:

  • antiviral drugs, antibodies and host-response modifiers, including their synthesis, in vitro and in vivo testing and mechanisms of action.
  • new or improved vaccines against viral infections of humans;
  • assessments of drug and vaccine safety;
  • evolution of drug- or vaccine-resistant viruses and the development of effective countermeasures;
  • identification and validation of new drug targets;
  • laboratory animal models of viral diseases;
  • pathogenesis of viral diseases and mechanisms of viral evasion of host immune responses.


We encourage the submission of manuscripts describing the activity of well-defined chemical compounds for the treatment of viral diseases of humans and vertebrate animals. We also publish manuscripts on the protective activity of vaccines for humans, and we will consider reports of the testing of veterinary vaccines in the target animal species. All papers must include a sufficiently detailed description of methods to permit other investigators to replicate the experiments. Authors reporting the antiviral effect of a novel small-molecule drug must reveal its chemical structure. Claims of in vitro or in vivo efficacy of a drug or vaccine must be supported by appropriate statistical analysis.


Note: Antiviral Research may choose not to publish certain COVID-19 papers.
The COVID-19 pandemic has focused attention on the possibility that patients infected with SARS-CoV-2 might benefit from treatment with certain licensed drugs approved for conditions other than viral infection. Reports that various medications inhibit the replication of the virus in vitro have been widely publicized in news articles and on medical websites, giving the impression that compounds still in the earliest stage of evaluation may be used to prevent or treat COVID-19. Such misunderstanding may result in the inappropriate use of a drug by physicians and to self-treatment by people who obtain it from other sources, with a risk of toxicity. This may be a particular problem when a medication is available without prescription as a veterinary product. Hoarding or inappropriate use of a drug intended to treat another disease may also make it unavailable to patients with that disease. The editors of Antiviral Research may therefore choose not to publish certain COVID-19 manuscripts, when in our judgment publication is likely to result in harm, without clear evidence of benefit.


The scope of AVR also includes the prevention and treatment of viral diseases of vertebrate animals. We do not publish reports on viral diseases of plants or of insects, crustaceans or other invertebrates. Studies of viral diseases of livestock and companion animals must be clearly related to the development of realistic therapies. Papers on veterinary vaccines should report findings in the target animal species.


We discourage the submission of manuscripts reporting the antiviral activity of unpurified natural products, or of partially purified substances of natural origin for which a mechanism of action has not been determined. Manuscripts claiming an antiviral effect of homeopathic products or other highly diluted preparations, or which fail to clearly identify the biological ingredient or molecule responsible for the antiviral activity of an experimental therapy, will not be considered for publication. Articles describing antiseptics with broad-spectrum antimicrobial activity will not be accepted. We also discourage submission of in silico docking studies or other computer-based predictions of antiviral activity that are not supported by data from biological assays. Citations of reports that have not undergone peer review must include the note "[not peer-reviewed]."


Antiviral Research is an official publication of the International Society for Antiviral Research (http://www.isar-icar.com).

Benefits to authors
We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services .

Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center

Product details

  • SCImago Journal Rank (SJR): 2.052
  • Source Normalized Impact per Paper (SNIP): 1.956
  • Impact Factor: 5.97
  • Five Year Impact Factor: 5.801
  • ISSN: 0166-3542
  • Issues: 12
  • Volume: 12
Editorial board

Author services

Prepare your article for submission

Celebrate your publication

Additional services

Publication schedule

Issue volumeIssue yearPlanned ship dateActual ship date
185C2021Jan 20, 2021Jan 19, 2021
186C2021Feb 19, 2021Feb 15, 2021
187C2021Mar 01, 2021Feb 23, 2021
188C2021Mar 30, 2021Mar 19, 2021
189C2021Apr 26, 2021Apr 26, 2021
190C2021Jun 02, 2021Jun 10, 2021
191C2021Jun 25, 2021Jun 24, 2021
192C2021Jul 28, 2021Jul 19, 2021
193C2021Aug 27, 2021Aug 16, 2021
194C2021Oct 07, 2021Oct 05, 2021
195C2021Nov 22, 2021
196C2021Dec 06, 2021
197C2022Jan 17, 2022
198C2022Feb 18, 2022
199C2022Mar 11, 2022
200C2022Mar 28, 2022
201C2022Apr 26, 2022
202C2022May 27, 2022
203C2022Jun 23, 2022
204C2022Jul 26, 2022
205C2022Aug 24, 2022
206C2022Sep 23, 2022
207C2022Oct 25, 2022
208C2022Dec 06, 2022